Respiratory infections and congenital heart disease: Two seasons of the civic study;Infecciones respiratorias y cardiopatías congénitas: Dos estaciones del estudio CIVIC

Anales de Pediatria

Volumn 67, Issue 4, 2007, Pages 329-336

  Medrano Lopez C ^a,b   Garcia Guereta Silva L ^a  

^a Sociedad Espanola de Cardiologia Pediatrica Y Cardiopatias Congenitas   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Bronchiolitis; Congenital heart disease; Delection 22q11; Epidemiology; Hospitalisation; Malnutrition; Respiratory infection; Respiratory syncytial virus; Trisomy 21

Indexed keywords

ARTICLE; BRONCHIOLITIS; CONGENITAL HEART DISEASE; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PNEUMONIA; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; SPAIN;

EID: 35448968855     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1157/13110605     Document Type: Article

References (31)

1. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data. National Center for Health Statistics. Vital Health Stat. 2005;13:1-199.
2. Bonnet D, Schmaltz AA, Feltes TF. Infection by the respiratory syncytial virus in infants and young children at high risk. Cardiol Young. 2005;15:256-65.
3. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med. 1982;307:397-400.
4. Khongphatthanayothin A, Wong PC, Samara Y, Newth CJL, Wells WJ, Starnes VA, et al. Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome. Crit Care Med. 1999;27:1974-81.
5. Altman CA, Englund JA, Demmler G, Drescher KL, Alexander MA, Watrin C, et al. Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening. Pediatr Cardiol 2000;21:433-8.
6. Carbonell-Estrany X, Figueras-Aloy J, Law BJ; IRIS Study Group; PICNIC Study group. Identifying risk factors for severe respiratory syncytial virus infection among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J. 2004;23: S193-201.
7. Carbonell-Estrany X, Quero Jiménez J. Comité de Estándares de la Sociedad Española de Neonatología. Recomendaciones para la prevención de la infección por el virus respiratorio sincitial: revisión. An Esp Pediatr. 2002;56:334-6.
8. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112:1442-6.
9. Suárez Cabrera P, Malo Concepción P, Maroto E, Santos de Soto J. Recomendaciones para la prevención de la infección por virus respiratorio sincitial en pacientes con cardiopatía congénita. Sociedad Española de Cardiología Pediátrica y Cardiopatías Congénitas 2003. http://www.secardioped.org/pdfs/ profilaxis_virus_vrs.pdf.
10. Medrano C, García-Guereta L, Grueso J, Insa B, Ballesteros F, Casaldáliga J, et al. On behalf of the CIVIC Study Group from the Spanish Society of Pediatric Cardiology and Congenital Heart Disease. Respiratory infection in congenital cardiac disease. Hospitalizations in young children in Spain during 2004 and 2005: The CIVIC epidemiologic Study. Cardiol Young. 2007;17:360-71.
11. Décima revisión de la clasificación estadística internacional de las enfermedades y de los problemas relacionados con la salud, de la Organización Mundial de la Salud 1995. http:// www3.who.int/icd/vol1htm2003/fr-icd.htm?kj00.htm+.
12. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al. Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532-40.
13. Zavanella C, Portela F, Rueda F, Medrano C. Valoración y estratificación del riesgo en cirugía cardíaca infantil. En: Otero E, Rufilanchas JJ y Belda FJ, editores. Riesgo y complicaciones en cirugía cardiaca. Buenos Aires-Madrid: Panamericana; 2004. p. 318-22.
14. Comité asesor de vacunas de la Asociación Española de Pediatría. Calendario de vacunación de la Asociación Española de Pediatría. An Pediatr (Barc). 2007;66:62-9.
15. Tablas de crecimiento (estudios longitudinal y transversal) del instituto de investigación sobre crecimiento y desarrollo Fundación Faustino Obergozo Eizaguirre, María Díaz de Haro, 10 bis. 48013 Bilbao. http://www.aepap. org/informat/index.htm.
16. Centers for Disease Control and Prevention (CDC). Brief Report: Respiratory Syncytial Virus Activity - United States, 2004-2005 MMWR Morb Mortal Wkly Rep. 2005;54:1259-60.
17. Pedraz C, Carbonell-Strany X, Figueras Aloy J, Quero J, IRIS Study Group. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infec Dis J. 2003;22:823-7.
18. Romero JR. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr Infect Dis J. 2003;22:S46-54.
19. Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, Pfammatter JP, Aebi C. Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arc Dis Child. 2004;89:961-5.
20. Eriksson M, Bennet R, Rotzen-Ostlund M, Von Sydow M, Wirgart BZ. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr. 2002;91:593-8.
21. Pignotti MS, Indolfi G, Donzelli G. Factors impacting compliance with palivizumab prophylaxis. Pediatr Infect Dis J. 2004;23:186-7.
22. Varan B, Tokel K, Yilmaz G. Malnutrition and growth failure in cyanotic and acyanotic congenital heart disease with and without pulmonary hypertension. Arch Dis Child. 1999;81:49-52.
23. Cashat-Cruz M, Morales-Aguirre JJ, Mendoza-Azpiri M. Respiratory tract infections in children in developing countries. Semin Pediatr Infect Dis. 2005;16:84-92.
24. Deerojanawong J, Chang AB, Eng PA, Robertson CF, Kemp AS. Pulmonary diseases in children with severe combined immune deficiency and DiGeorge syndrome. Pediatr Pulmonol. 1997; 24:324-30.
25. Hilton JM, Fitzgerald DA, Cooper DM. Respiratory morbidity of hospitalized children with trisomy 21. J Paediatr Child Health. 1999;35:383-6.
26. Simoes EAF, Carbonell-Estrany X. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries. Pediatr Infect Dis J. 2003;22:S13-20.
27. Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, Ziegler T, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics. 2004;113:701-7.
28. Poehling KA, Edwaards KM, Weinberg GA, Szilagyi P, Staat MA, Iwane K, et al. for the New Vaccine Surveillance Network. The underrecognized burden of influenza in young children. N Eng J Med. 2006;355:31-40.
29. Quach C, Piche-Walker L, Platt R, Moore D. Risk factors associated with severe influenza infections in childhood: implication for vaccine strategy. Pediatrics. 2003;112:197-201.
30. Purcell K, Fergie J. Driscoll children's hospital respiratory syncytial virus database. Risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002. Pediatr Infect Dis J. 2004;223:418-3.
31. Navas L, Wang E, de Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr. 1992;121:348-54.